PARIS--(BUSINESS WIRE)--AB Science SA (Paris:AB)(NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of results from the first human phase 2 study of masitinib carried-out in the treatment of Alzheimer’s disease. Entitled, ‘Masitinib as an adjunct therapy for mild-to-moderate Alzheimer’s disease: a randomised, placebo-controlled phase 2 trial’, this article is freely accessible online from BioMed Central’s peer-reviewed journal Alzheimer’s Research and Therapy (http://alzres.com/content/3/2/16).
